Abstract
Allosteric effectors of hemoglobin (AEH) remain promising as a viable therapeutic approach for the management of sickle cell disease (SCD). AEH bind to hemoglobin (Hb) in a transiently covalently manner, increasing Hb affinity for oxygen (O2), with concomitant inhibition of polymerization of deoxygenated sickle Hb (HbS) and erythrocyte sickling. As part of our ongoing efforts to surmount well-known AEH druggability challenges, we have designed and synthesized VZHE-039, a novel substituted benzaldehyde with potent in-vitro anti-polymerization activity, as well as more favorable in-vivopharmacokinetic and pharmacodynamic (PK/PD) properties. Here, we report the results of our early findings.
The anti-sickling properties of VZHE-039 were tested in-vitro by incubating 0.5, 1, and 2 mM concentrations with blood suspensions from a subject with homozygous SCD (hematocrit: 20%) under hypoxic conditions (4% O2/96% N2) at 37°C for 2 h. At conclusion, aliquots were drawn into a fixative (2% glutaraldehyde solution), and sickling was assessed by microscopy. Aliquot samples were also subjected to cation-exchange HPLC analyses to measure the degree of Hb modification (Hb adduct formation), as well as standard O2 equilibrium curves (OEC) to assess p50 shifts. Subsequently, we conducted in-vivo PK/PD studies in wild-type mice that received single doses of VZHE-039 via the intravenous (I.V.: 25 and 50 mg/kg), intraperitoneal (I.P.: 100-150 mg/kg) and oral (P.O.: 100-200 mg/kg) routes. Serial blood samples were collected up to 24 h after I.V. and P.O., and up to 6 h after I.P. administration, respectively; aliquots were hemolyzed, de-proteinized and subjected to reverse-phase HPLC-UV assay to quantify VZH-039 blood concentrations. Residual blood samples were also hemolyzed, and clarified lysates were assayed for in-vivoHb adduct formation, and the corresponding change in Hb oxygen affinity (Δp50, %).
The results of our in-vitrostudies demonstrated a concentration-dependent inhibition of SS cell sickling: 39±1.4%, 68.6±4.9%, and 89.9±5.2%, at 0.5, 1 and 2 mM of VZHE-039, respectively. HbS was modified correspondingly (46±7.4%, 83.6±6.4%, and 96.4±6.2%), and this adduct formation was correlated linearly with the left shift in OEC (Δp50 values of 34.3±8.7%, 63.6±2.4%, and 76.6±2.5%).
Noncompartmental PK analysis showed that, after I.V. administration, systemic PK was dose-independent with a CLtot of 0.5 mL/min/kg, resulting in a terminal half-life of 9 h. After I.P. administration, AUCtrap increased supra-proportionally with dose; the limited sampling schedule suggested an I.P. bioavailability of >20%. After P.O. administration, AUCtrap increased supra-proportionally with dose as well due to an increase in oral bioavailability to ~ 10%, with peak blood concentrations up to ~ 0.25 mM; the terminal half-lives were prolonged (relative to I.V.) to 14 h. The PD effect-time course of change in %Hb adduct paralleled (and was reasonably linearly related to) blood concentrations for all routes. Baseline-corrected peak PD effects after I.V. administration were 15.7% and 31.9%, after 25 and 50 mg/kg respectively; after P.O. administration of 200 mg/kg, the peak change was 17.6%. Overall, VZHE-039 exhibited a low (metabolic) clearance, presumably reflecting high-affinity and sustained Hb (and possibly albumin) binding, leading to the observed extended terminal half-life and duration of action. While its oral bioavailability is low (likely due to limited GI solubility) and there is evidence of saturable first-pass effects and possibly enterohepatic recycling, oral in-vivo exposures were associated with PD effects that were consistent with the results from the in-vitrostudies.
In conclusion, the results of our current studies establish VZHE-039 as a novel, potent anti-sickling agent, confirm its proposed mechanism of action in-vitro and in-vivo, and suggest that therapeutically-relevant blood concentrations may be achieved after daily oral doses. Therefore, VZHE-039 is our new lead drug candidate that may require further modifications and studies to (a) improve its GI solubility and oral bioavailability; (b) elucidate atomic level structural interactions and kinetics of its Hb binding; and (c) formally investigate its biological activity after repeat-doses in a SCD mouse model.
Disclosures
No relevant conflicts of interest to declare.
Pharmacokinetics of Doxycycline in Adults with Cystic Fibrosis